ASH 2023 Multiple Myeloma

CE / CME

Conference to Clinic: Expert Analysis of the Top Multiple Myeloma Abstracts From the 2023 ASH Annual Meeting

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurses: 1.00 Nursing contact hour

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

Released: March 07, 2024

Expiration: March 06, 2025

Sagar Lonial
Sagar Lonial, MD, FACP

Activity

Progress
1 2
Course Completed

Introduction

In this module, Dr Sagar Lonial discusses key findings in multiple myeloma presented at the 2023 American Society of Hematology (ASH) Annual Meeting.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slidesets, which can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. The questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following question.

For those providing patient care, how many patients with multiple myeloma do you provide care for in a typical month?

A 55-year-old man was diagnosed with active multiple myeloma (multiple lytic lesions in vertebrae) and FISH showed gain 1q positivity and t(4;14) translocation​. Which induction therapy would you recommend for this patient?​

In the phase I/II LINKER-MM1 trial for patients with relapsed/refractory (R/R) multiple myeloma after ≥3 previous lines of therapy including ≥1 immunomodulatory drug (IMiD), ≥1 proteasome inhibitor (PI), and an anti-CD38 monoclonal antibody (mAb)​, which of the following outcomes was reported for linvoseltamab?

Which of the following results was reported in the phase I/II study for patients with R/R multiple myeloma and t(11;14) translocation receiving venetoclax + daratumumab/dexamethasone vs those receiving bortezomib + daratumumab/dexamethasone?